ArticleParkinsonism & related disorders2025
No anti-IgLON5 antibody in carefully diagnosed PSP patients with "atypical" or variant clinical features.
Article in Parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuronal Antibodies in Patients With Atypical Parkinsonism.Neurology(R) neuroimmunology & neuroinflammation · 2026Observational
- Breaking barriers and fighting inequality in Parkinson's disease care: Personal reflections of movement disorders clinicians.Journal of Parkinson's disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
background"Atypical" features including REM sleep behaviour disorder (RBD) symptoms and visual hallucinations, and non-Richardson's syndrome (non-RS) variants, are increasingly recognized in progressive supranuclear palsy (PSP). A concern in clinical practice is missing PSP mimics, like anti-IgLON5 disease, an autoimmune encephalitis which can reportedly present with "PSP-like" features and is amenable to immunotherapy. We aimed to determine if anti-IgLON5 antibody is detectable in Movement Disorder Society criteria-diagnosed PSP patients exhibiting "atypical" features and variant phenotypes.
methodsThis was a cross-sectional study of 64 multi-ethnic Asian PSP patients who were recruited via convenience sampling from June 2023-April 2025. Patients were extensively phenotyped by movement disorder neurologists, and their sera tested for immunoglobulin G against IgLON5, using cell-based assays at a neuroimmunology reference laboratory.
results37.5 % of the cohort had a non-RS phenotype, and 39.1 % had RBD symptoms and/or non-predominant visual hallucinations. Additionally, when the presence of other features that could be associated with a higher likelihood of anti-IgLON5 disease were also accounted for (i.e., comorbid autoimmune disease, orofacial dyskinesia, protracted disease duration, and/or lack of downgaze-predominant oculomotor abnormalities), these patients comprised 95.3 % of the cohort. Despite this, none tested positive for anti-IgLON5 antibody.
conclusionOur results suggest that routine testing for anti-IgLON5 antibody in patients carefully diagnosed with PSP in movement disorder clinics is likely to be of very low yield. However, testing in research settings of larger cohorts of atypical and variant PSP presentations, applying consensus diagnostic criteria and detailed phenotypic characterization, may currently still be of value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.